Q1 EPS Estimates for Nuvation Bio Decreased by HC Wainwright

Nuvation Bio Inc. (NYSE:NUVB) – Research analysts at HC Wainwright reduced their Q1 2025 earnings per share (EPS) estimates for shares of Nuvation Bio in a report released on Monday, March 10th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings per share of ($0.17) for the quarter, down from their prior estimate of ($0.15). HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Nuvation Bio’s current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Nuvation Bio’s Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.17) EPS and FY2025 earnings at ($0.71) EPS.

Several other research analysts have also commented on the stock. Jones Trading began coverage on shares of Nuvation Bio in a research note on Wednesday. They set a “buy” rating and a $10.00 price objective for the company. Wedbush reaffirmed an “outperform” rating and set a $5.00 price target on shares of Nuvation Bio in a research report on Monday, March 3rd. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $10.00 price target (up previously from $6.00) on shares of Nuvation Bio in a report on Tuesday, January 7th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $8.33.

Nuvation Bio Stock Performance

Shares of Nuvation Bio stock opened at $2.25 on Wednesday. The company has a market capitalization of $755.59 million, a PE ratio of -1.03 and a beta of 1.47. The company has a 50-day simple moving average of $2.38 and a two-hundred day simple moving average of $2.57. Nuvation Bio has a one year low of $1.67 and a one year high of $4.16.

Hedge Funds Weigh In On Nuvation Bio

Several institutional investors have recently made changes to their positions in the company. Forum Financial Management LP purchased a new position in Nuvation Bio in the fourth quarter valued at $29,000. Cerity Partners LLC purchased a new position in shares of Nuvation Bio in the 4th quarter valued at about $31,000. Russell Investments Group Ltd. raised its holdings in Nuvation Bio by 15,183.7% in the 4th quarter. Russell Investments Group Ltd. now owns 15,895 shares of the company’s stock worth $42,000 after purchasing an additional 15,791 shares during the period. Abacus Planning Group Inc. purchased a new position in Nuvation Bio during the fourth quarter worth approximately $44,000. Finally, Cibc World Markets Corp purchased a new position in Nuvation Bio during the fourth quarter worth approximately $45,000. 61.67% of the stock is owned by hedge funds and other institutional investors.

Nuvation Bio Company Profile

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.